SRSD384

SRSD384 is an investigational liver-targeted small interfering RNA (siRNA) therapeutic developed by Sirius Therapeutics for the treatment of obesity. It is designed to silence the expression of the *INHBE* (Inhibin subunit beta E) gene in the liver. By reducing INHBE levels, the drug aims to mimic natural human loss-of-function mutations that are associated with a healthy metabolic profile, including reduced abdominal fat and improved insulin sensitivity. SRSD384 works through a non-incretin pathway to modulate energy expenditure, potentially promoting fat loss while preserving skeletal muscle mass—a key advantage over traditional GLP-1 receptor agonists. The asset is currently advancing toward Investigational New Drug (IND) submission.